XOMAP (XOMA Corporation) Stock Financials & Earnings | Market Cap Arena

XOMAP (XOMA Corporation) Stock Financials & Earnings | Market Cap Arena

XOMAPXOMA Corporation

Mkt Cap$311M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$47M

Net Income (TTM)$22M

EPS (TTM)$2.10

Free Cash Flow (TTM)$5M

Gross Margin93.6%

Op. Margin-15.0%

Net Margin45.9%

FCF Margin11.4%

P/S Ratio (TTM)6.6x

P/E Ratio (TTM)14.3x

YoY Rev Growth+118.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q4 22	$1M	$1M	-$6M
Q1 23	$437K	$383K	-$10M
Q2 23	$2M	$2M	-$6M
Q3 23	$830K	$805K	-$6M
Q4 23	$2M	$2M	-$20M
Q1 24	$1M	$1M	-$7M
Q2 24	$11M	$10M	-$10M
Q3 24	$7M	$7M	-$16M
Q4 24	$9M	$9M	-$16M
Q1 25	$16M	$15M	$6M
Q2 25	$13M	$12M	$5M
Q3 25	$9M	$8M	-$1M

Valuation

Quarter	P/S	P/E
Q4 22	51.5x	—
Q1 23	92.5x	—
Q2 23	77.0x	—
Q3 23	70.4x	—
Q4 23	65.3x	—
Q1 24	53.4x	—
Q2 24	20.4x	—
Q3 24	14.4x	—
Q4 24	10.9x	—
Q1 25	7.2x	—
Q2 25	6.9x	—
Q3 25	6.6x	14.3x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 22	-$4M	-$4M
Q1 23	-$5M	-$5M
Q2 23	-$7M	-$7M
Q3 23	-$2M	-$2M
Q4 23	-$4M	-$4M
Q1 24	-$6M	-$6M
Q2 24	$3M	$3M
Q3 24	-$9M	-$9M
Q4 24	-$3M	-$3M
Q1 25	$2M	$2M
Q2 25	$6M	$6M
Q3 25	-$296K	-$296K

Capital Expenditures

CapEx

Quarter	CapEx
Q4 22	$0
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$17K
Q1 24	$17K
Q2 24	$0
Q3 24	$0
Q4 24	$3K
Q1 25	$0
Q2 25	$0
Q3 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 22	-95.9%	+37.9%
Q1 23	-85.9%	+105.1%
Q2 23	+68.7%	+32.4%
Q3 23	+84.0%	+37.2%
Q4 23	+23.4%	+182.8%
Q1 24	+241.0%	-19.9%
Q2 24	+568.6%	+177.9%
Q3 24	+767.1%	+245.1%
Q4 24	+375.4%	+14.7%
Q1 25	+967.9%	+17.5%
Q2 25	+18.4%	-59.7%
Q3 25	+29.9%	-53.2%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 22	$0	0.0%
Q1 23	$2M	359.3%
Q2 23	$0	0.0%
Q3 23	$3M	327.3%
Q4 23	$3M	144.5%
Q1 24	$0	0.0%
Q2 24	$3M	24.3%
Q3 24	$0	0.0%
Q4 24	$0	0.0%
Q1 25	$2M	12.5%
Q2 25	$0	0.0%
Q3 25	$0	0.0%

OpEx Breakdown

Quarter	R&D	G&A	S&M
Q4 22	$28K	$8M	$47K
Q1 23	$54K	$6M	$53K
Q2 23	$39K	$6M	$58K
Q3 23	$25K	$6M	$37K
Q4 23	$25K	$7M	$1M
Q1 24	$33K	$8M	—
Q2 24	$1M	$11M	$9M
Q3 24	$817K	$8M	—
Q4 24	$864K	$7M	$5K
Q1 25	$1M	$8M	$33K
Q2 25	$69K	$8M	—
Q3 25	$69K	$10M	—

War Chest

Quarter	Cash	Short-term Investments	Total
Q4 22	$58M	$335K	$58M
Q1 23	$44M	$311K	$45M
Q2 23	$31M	$320K	$32M
Q3 23	$33M	$214K	$34M
Q4 23	$153M	$161K	$153M
Q1 24	$136M	$413K	$137M
Q2 24	$144M	$696K	$145M
Q3 24	$142M	$785K	$143M
Q4 24	$102M	$4M	$105M
Q1 25	$90M	$2M	$93M
Q2 25	$75M	$9M	$84M
Q3 25	$90M	$2M	$92M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q4 22	11M	+0.0%
Q1 23	11M	+0.1%
Q2 23	11M	+0.1%
Q3 23	11M	+0.1%
Q4 23	11M	+0.0%
Q1 24	12M	+0.9%
Q2 24	12M	+0.6%
Q3 24	12M	+0.6%
Q4 24	12M	+1.2%
Q1 25	12M	+0.0%
Q2 25	15M	+26.5%
Q3 25	18M	+21.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 13	$211K	168
FY 14	$103K	183
FY 15	$645K	86
FY 16	$309K	18
FY 17	$4M	12
FY 18	$482K	11
FY 19	$2M	10
FY 20	$3M	10
FY 21	$3M	12
FY 22	$502K	12
FY 23	$366K	13
FY 24	$2M	13